subscribeSubscribe
Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug
Zachary Brennan ENDPTS
09 Apr 2024
Share Share
Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome

Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome
PR NEWSWIRE
08 Apr 2024
Share Share
Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide

Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide
PR NEWSWIRE
12 Jun 2023
Share Share
Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia

Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia
PR NEWSWIRE
30 May 2023
Share Share
Stealth granted FDA meeting to revive elamipretide filing

Stealth granted FDA meeting to revive elamipretide filing
Annalee Armstrong FIERCEBIOTECH
15 Jun 2022
Share Share
Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide

Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide
PRNEWSWIRE
23 May 2022
Share Share
Stealth BioTherapeutics Receives ODD for Elamipretide in DMD

Stealth BioTherapeutics Receives ODD for Elamipretide in DMD
PRNEWSWIRE
12 May 2022
Share Share
Stealth Bio Posts Disappointing Data From Mid-Stage Geographic Atrophy Study

Stealth Bio Posts Disappointing Data From Mid-Stage Geographic Atrophy Study
V. Singh BENZINGA
03 May 2022
Share Share
Stealth BioTherapeutics` Completes Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics` Completes Phase 2 Geographic Atrophy Clinical Trial
PRNEWSWIRE
15 Feb 2022
Share Share
Stealth BioTherapeutics Announces Oral Presentation of New DMD Data

Stealth BioTherapeutics Announces Oral Presentation of New DMD Data
PRNEWSWIRE
08 Feb 2022
Share Share